Mirion Technologies, Inc. — 2021 Form 10-K
Business context and reporting period. Mirion supplies radiation detection, measurement, analysis and monitoring products, services and software. Its reportable segments are Medical and Industrial, serving medical, nuclear energy, defense, laboratory and research markets. The filing covers the year ended December 31, 2021, but it is a transition year: Mirion changed its fiscal year-end from June 30 to December 31 and completed its business combination on October 20. Results are split between the Predecessor period (July 1–October 19) and Successor period (October 20–December 31); acquisition accounting makes these periods not directly comparable.
Financial performance and position
| Metric | Reported amount or comparison |
|---|---|
| Transition-period revenue | $168.0 million Predecessor; $154.1 million Successor. Successor revenue included $49.2 million Medical and $104.9 million Industrial. |
| Prior fiscal-year comparison | For the fiscal year ended June 30, 2021, revenue was $611.6 million, up 27.9% from $478.2 million in fiscal 2020. The filing attributes most growth to acquisitions, particularly in Medical, and organic growth in Industrial. |
| Profit and operating margin | Net loss was $158.4 million in fiscal 2021 versus $119.1 million in fiscal 2020. Fiscal 2021 gross profit was $251.8 million, a 41.2% gross margin, approximately unchanged from fiscal 2020. Operating income fell to $11.2 million from $23.0 million. |
| Transition-period results | Net losses were $105.7 million in the Predecessor stub and $23.0 million in the Successor period. Successor gross margin was 35.0%, affected by a $15.8 million inventory fair-value step-up; Predecessor stub gross margin was 41.8%. |
| Cash flow | Net operating cash flow was $(12.2) million in the Successor period and $13.1 million in the Predecessor stub. Fiscal 2021 operating cash flow was $53.6 million. Reported free cash flow was $(18.2) million Successor, $1.5 million Predecessor stub and $30.4 million in fiscal 2021; free cash flow is a non-GAAP measure. |
| Liquidity | Cash and cash equivalents were $84.0 million at December 31, 2021, versus $101.1 million at June 30, 2021. Current assets were $453.4 million and current liabilities $221.0 million. |
| Debt | Third-party borrowings totaled $831.8 million gross ($810.7 million net of unamortized financing costs); $828.3 million was outstanding under the new term loan. The $90 million revolver had no borrowings, with approximately $81.9 million available after letters of credit. Term loan rate was 3.25% at year-end; debt is largely floating-rate. |
| Backlog and deferred revenue | Backlog was $747.5 million, up from $715.8 million at June 30, 2021; about 45% was expected to be recognized in calendar 2022. Deferred contract revenue was $73.0 million. |
Management reported adequate liquidity for the next 12 months, assuming operating cash flow and existing debt arrangements. The filing also reports $1.66 billion of goodwill and $806.9 million of net intangible assets at year-end, substantially reflecting acquisition accounting.
Material changes and unusual items
- The October 20 business combination involved approximately $1.3 billion cash consideration, newly issued shares, and a $900 million PIPE investment. Mirion refinanced prior debt with an $830 million term loan and $90 million revolving facility; shareholder and management notes were extinguished.
- The acquisition-method fair-value step-up materially affects comparability, including $32.0 million of Successor-period acquired-intangible amortization and $15.8 million of inventory step-up cost. The purchase-price allocation remained provisional at filing.
- Medical revenue growth was largely acquisition-driven. CIRS was acquired for approximately $55.1 million gross consideration in December 2021, alongside smaller dosimetry acquisitions.
- The Company reported a $15.9 million debt-extinguishment loss in the Predecessor stub period and substantial transaction, public-company preparation, integration and restructuring expenses. Successor-period warrant fair-value changes generated a $1.2 million non-cash gain.
- The Company reported a voluntary FDA recall affecting 1,256 AtomLab 500 and AtomLab 500 Plus units because of a software error affecting custom isotope lists; corrected software had been released in June 2021.
- A February 2021 ransomware incident resulted in unauthorized access and publication of certain personal and proprietary information. Mirion reported the incident to authorities and said it had added security measures.
Outlook, commentary and principal risks
Management initiated calendar 2022 guidance of 5%–7% organic adjusted revenue growth and $175 million–$185 million adjusted EBITDA. These are non-GAAP measures; the filing cautions that non-GAAP measures are not substitutes for GAAP results and may not be comparable across companies.
- Management cites opportunities in medical diagnostics and therapy, dosimetry outsourcing, nuclear reactor upgrades and new builds, decommissioning, and defense radiation detection. Backlog provides visibility but is not guaranteed revenue: an estimated 10%–15% may relate to unfunded contracts at risk of cancellation.
- Supply constraints, semiconductor shortages, labor and freight costs, commodity inflation and fixed-price contracts could pressure delivery, costs and margins; passing through higher costs may be difficult.
- COVID-19 had caused disruptions, customer delays and disputes, collection delays, site-access limitations and staffing challenges. Its future effects were uncertain.
- Other significant risks include high leverage and floating interest rates, acquisitions and integration, customer and government budget timing, long sales cycles, foreign exchange, regulatory and product-liability exposure, cybersecurity, and export controls and sanctions. The filing specifically notes potential effects of new Russia-related sanctions and controls on existing contracts and backlog.
- Mirion reported that it complied with debt covenants at December 31, 2021. It had no cash-dividend history and did not expect to pay dividends in the foreseeable future.
- The financial-statement auditor issued an unqualified opinion. Management did not assess internal control over financial reporting for year-end 2021, citing unreasonable effort or expense; management stated the earlier GSAH material weakness concerning accounting for complex shares and warrants had been remediated. Disclosure controls were assessed as effective.
Key investor verification points
- Review full-year and quarterly results on a consistent basis: calendar-year 2021 revenue and earnings are not presented as one comparable full-year operating period, and the Successor and Predecessor periods use different accounting bases.
- Reconcile 2022 guidance to GAAP revenue and earnings, and assess its assumptions, organic-growth definition and adjusted EBITDA exclusions.
- Test backlog quality, funding status, expected conversion timing and profitability, including the unfunded portion and exposure to project delays or cancellations.
- Assess debt-service capacity, floating-rate sensitivity, covenant headroom, revolver availability and cash accessibility at subsidiaries.
- Track acquisition integration, the final purchase-price allocation, acquired-asset amortization, goodwill impairment indicators and the durability of Medical-segment margins.
- Verify progress on internal-control testing and remediation, and monitor cybersecurity response, the medical-device recall and any resulting claims or regulatory actions.